(UroToday.com) The 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 16th and 18th was host to a prostate cancer poster session. Dr. Lisa Gudenkauf presented the framework for FACT-RNT, a novel patient-reported outcome measure for patients with prostate cancer receiving radionuclide therapy.
Dr. Gudenkauf noted that the field of targeted radionuclide therapy (RNT) for prostate cancer is rapidly growing with the recent FDA approval of the first lutetium-177-PSMA-ligand.1 Currently available patient-reported outcome (PRO) measures were designed to evaluate the impact of traditional, non-radionuclide therapies (e.g. chemotherapy, surgery). As such, there is a clinical unmet need for PRO measure assessments for patient prostate cancer patients receiving RNT.
The authors utilized a qualitative methods approach, using input from experts, patients, and caregivers. Potential RNT-related symptoms and toxicities were identified via a literature review of published trials and interviews with prostate cancer patients who had received RNT, caregivers of RNT recipients, and clinicians. The Functional Assessment of Chronic Illness Therapy (FACIT) item library was used to identify items to include in the measure.
Interviews were conducted with 29 patients who had received RNT, 14 caregivers, and 11 clinicians to identify relevant symptoms/toxicities (in addition to those identified via the literature search). Starting with a broad and comprehensive list of items from the FACIT item library, the authors refined the list following input from nine experts in the field of RNTs and PROs from 5 institutions. Subsequently, patients who received RNT for PC (n=11) reviewed the draft measure and confirmed that the items were comprehensible and relevant to RNT recipients. This resulted in a brief 15-item measure deemed by key stakeholders to be relevant and useful in the context of RNT for prostate cancer.
The FACT-RNT (Functional Assessment of Cancer Therapy – Radionuclide Therapy) is an RNT-specific PROs measure for patients receiving RNTs, developed through a multi-disciplinary collaboration with patients, caregivers, clinicians, and international experts. The FACT-RNT can be used in RNT clinical trials and real-world settings.
Presented by: Lisa M. Gudenkauf, PhD, Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL
Written by: Rashid Sayyid, MD, MSc – Society of Urologic Oncology (SUO) Clinical Fellow at The University of Toronto, @rksayyid on Twitter during the 2023 Genitourinary (GU) American Society of Clinical Oncology (ASCO) Annual Meeting, San Francisco, Thurs, Feb 16 – Sat, Feb 18, 2023.
References:
- Fallah J, et al. FDA Approval Summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2022;CCR-22-2875.
A Novel Patient-reported Outcome Measure for Patients With Prostate Cancer Receiving Radionuclide Therapy: FACT-RNT - Lisa Gudenkauf